



July 2004

POCT14-A

Point-of-Care Monitoring of Anticoagulation Therapy; Approved Guideline

This document provides guidance to users and manufacturers of point-of-care coagulation devices for monitoring heparin and warfarin anticoagulant therapy, and to ensure reliable results comparable to those obtained by routine clinical laboratory testing.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in clinical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Administrative Procedures.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: 610.688.0100
F: 610.688.0700
www.clsi.org
standard@cls.org

ISBN 1-56238-540-2

ISSN 0273-3099

POCT14-A

Vol. 24 No. 23

Formerly H49-A

Vol. 24 No. 23

Point-of-Care Monitoring of Anticoagulation Therapy; Approved Guideline

Volume 24 Number 23

J. Heinrich Joist, M.D., Ph.D.

Jack E. Ansell, M.D.

George G. Despotis, M.D.

Frank LaDuca, Ph.D.

Richard A. Marlar, Ph.D.

Ginette Y. Michaud, M.D.

David L. Phillips

Paula J. Santrach, M.D.

Abstract

Point-of-care coagulation testing (POC-CT), also known as “bedside testing” or “near-patient testing,” is intended to provide test results more rapidly than can be achieved in hospital or reference laboratory settings. This is important in intensive care units, emergency rooms, operating rooms, and outpatient clinics, where it may help to expedite treatment decisions. POCT allows coagulation testing in the home environment, including patient self-testing (PST), thus providing increased access and convenience for the patient and/or caregiver and improving quality of care.

The guideline provides users of POC-CT systems with information and suggestions for good clinical testing practice and for producing reliable test results regardless of where or by whom the test is performed. This document deals with POC-CT performed for monitoring heparin and warfarin therapy.

CLSI. *Point-of-Care Monitoring of Anticoagulation Therapy; Approved Guideline*. CLSI document POCT14-A (ISBN 1-56238-540-2). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2004.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsii.org; Website: www.clsi.org.



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE®

Copyright ©2004 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Point-of-Care Monitoring of Anticoagulation Therapy; Approved Guideline*. CLSI document POCT14-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2004.

Proposed Guideline

September 2003

Approved Guideline

July 2004

ISBN 1-56238-540-2
ISSN 0273-3099

Committee Membership

Area Committee on Hematology

Bruce H. Davis, M.D.
Chairholder
Maine Medical Center Research Institute
Scarborough, Maine

Samuel J. Machin, MB, Ch.B,
FRCPPath, FRCP
Vice-Chairholder
The University College London Hospitals
London, United Kingdom

Dorothy M. Adcock, M.D.
Esoterix Coagulation
Aurora, Colorado

Frank M. LaDuca, Ph.D.
International Technidyne Corporation
Edison, New Jersey

Ginette Y. Michaud, M.D.
Center for Devices and Radiologic Health
Food and Drug Administration
Rockville, Maryland

Albert Rabinovitch, M.D., Ph.D.
Hematology Business Unit
Abbott Diagnostics Division
Santa Clara, California

Maryalice Stetler-Stevenson, M.D., Ph.D.
National Institutes of Health
Bethesda, Maryland

Advisors

Charles F. Arkin, M.D.
Lahey Clinic
Burlington, Massachusetts

J. David Bessman, M.D.
University of Texas Medical Branch
Galveston, Texas

Sheila Clover, CPT(ASCP)(NCA)
Phlebotomy West
Brentwood, California

Dennis J. Ernst, M.T.(ASCP)
Center for Phlebotomy Education
Ramsey, Indiana

John A. Koepke, M.D.
Durham, North Carolina

Francis Lacombe, M.D., Ph.D.
Hôpital Haut-Lévêque
Pessac, France

Richard A. Marlar, Ph.D.
Oklahoma City VA Medical Center
Oklahoma City, Oklahoma

Diane I. Szamosi, M.A.,
M.T.(ASCP)SH
Greiner Bio-One,
VACUETTE North America, Inc.
Monroe, North Carolina

Luc Van Hove, M.D., Ph.D.
Abbott Laboratories
Abbott Park, Illinois

Subcommittee on Point-of-Care Coagulation Testing

Jack E. Ansell, M.D.
Chairholder
Boston University Medical Center
Boston, Massachusetts

George G. Despotis, M.D.
Washington University School of
Medicine
St. Louis, Missouri

Frank M. LaDuca, Ph.D.
International Technidyne Corporation
Edison, New Jersey

Richard A. Marlar, Ph.D.
Denver VA Medical Center
Denver, Colorado

Ginette Y. Michaud, M.D.
FDA Center for Devices/Rad. Health
Rockville, Maryland

David L. Phillips
i-Stat Corp.
East Windsor, New Jersey

Paula J. Santrach, M.D.
Mayo Clinic
Rochester, Minnesota

Advisors

Sue S. Beglinger, M.S., M.T.(ASCP)
University of Wisconsin
Madison, Wisconsin

J. David Bessman, M.D.
University of Texas Medical Branch
Galveston, Texas

Mary F. Cavin
John L. McClellan Memorial VA Hospital
Irvine, California

W. Gregory Cooper
Bio-Rad Laboratories, ECS Division
Indianapolis, Indiana

Catherine Cox, M.D.
Methodist Hospital of Indiana
Indianapolis, Indiana

Amando D'Angelo
H.S. Raffaele
Milan, Italy

Paul A. Foster, M.D.
Abbott Laboratories
Abbott Park, Illinois

Kenneth D. Levy
Roche Diagnostics Corporation
Indianapolis, Indiana

Marilyn Lightfoote
FDA Center for Devices/Rad. Health
Rockville, Maryland

Janice Marks
Health Park Medical Center
Fort Myers, Florida

Valerie L. Ng, Ph.D., M.D.
San Francisco General Hospital
San Francisco, California

John D. Olson, M.D.
University of Iowa Hospitals and Clinics
Iowa City, Iowa

Staff

David E. Sterry, M.T.(ASCP)
Staff Liaison
NCCLS
Wayne, Pennsylvania

Donna M. Wilhelm
Editor
NCCLS
Wayne, Pennsylvania

Melissa A. Lewis
Assistant Editor
NCCLS
Wayne, Pennsylvania

Acknowledgement

NCCLS gratefully acknowledges the late Dr. J. Heinrich Joist, St. Louis University Health Sciences Center, who served as the Chairholder from the development through the completion of the proposed-level guideline.

Contents

Abstract.....	i
Committee Membership.....	iii
Foreword.....	vii
1 Scope.....	1
2 Introduction.....	1
3 Standard Precautions.....	1
4 Definitions	1
5 Point-of-Care Coagulation Testing (POC-CT)—General Considerations.....	6
6 Quality Management: General Considerations for Point-of-Care Coagulation Testing	6
6.1 Operators, Materials, and Performance of POC-CT	6
6.2 Training.....	7
6.3 Quality Control and Proficiency Testing	8
6.4 Result Recording and Reporting	9
7 Monitoring Heparin Therapy	10
7.1 Introduction.....	10
7.2 Blood Specimen Collection and Handling.....	11
7.3 POC-CT Systems Used for Monitoring Heparin Therapy.....	11
7.4 Specific Applications	14
8 Monitoring Warfarin Therapy.....	15
8.1 Introduction.....	15
8.2 Blood Specimen Collection and Handling.....	15
8.3 Test Systems Used for Monitoring Warfarin Therapy.....	16
8.4 Specific Applications	18
8.5 Result Recording and Reporting	19
References.....	20
Summary of Delegate Comments and Subcommittee Responses.....	22
The Quality System Approach.....	26
Related NCCLS Publications.....	27

Foreword

Medical conditions, physical location of the patient, and treatment regimens often require test results to be obtained quickly, so appropriate medical care can be administered expeditiously. Laboratory medicine professionals are challenged by the increasing demands for providing faster turnaround of test results, without compromising accuracy. The need to provide test results at greater convenience to, and increased efficiency for, the patient/caregiver without compromising cost-effectiveness is also recognized.

With the introduction of portable devices capable of producing results within seconds or minutes, point-of-care testing (POC—also referred to as “near-patient testing” or “bedside testing”), has been evolving as one way to meet these demands. Because of the potentially serious consequences of inaccurate test results, it is essential that results are accurate and reliable.

One of the challenges facing the healthcare community is acceptance of the idea that clinical coagulation testing, traditionally performed by and under the supervision of trained laboratory professionals, may be performed by personnel not trained in clinical laboratory practice or by patients/caregivers in the home. However, it is the responsibility of the manufacturer to provide test systems capable of delivering accurate results when used properly. Professionals in laboratory medicine should support high-quality point-of-care coagulation testing (POC-CT) services. POC-CT has been, and will continue to be implemented in different sites within the hospital, e.g., operating room, emergency room, intensive care unit, postsurgical recovery room, hemodialysis unit, ambulatory care site, and the patient’s home. The selection of patients for patient self-testing (PST) is the responsibility of the treating physician.

This document provides information to users on how to proceed in the evaluation, implementation, and monitoring of POC-CT, and deals only with the use of POC-CT in monitoring of anticoagulant therapy. It does not address issues related to the use of POC-CT in the evaluation of patients with suspected bleeding disorders. The guideline was written under the assumption that most users may not be laboratory professionals and provides important definitions, procedures, and recommendations. The format is designed to be easy to follow for the lay user.

This document relates closely to NCCLS documents EP18—*Quality Management for Unit-Use Testing* and AST2—*Point-of-Care In Vitro Diagnostic (IVD) Testing*. Please refer to these documents for additional information.

A Note on Terminology

NCCLS, as a global leader in standardization and harmonization, is firmly committed to achieving global harmonization wherever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. NCCLS recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in NCCLS, ISO, and CEN documents; and that legally required use of terms, regional usage, and different consensus timelines are all obstacles to harmonization. In light of this, NCCLS recognizes that harmonization of terms facilitates the global application of standards and is an area of immediate attention. Implementation of this policy must be an evolutionary and educational process that begins with new projects and revisions of existing documents.

In order to align the terminology used in POCT14-A with ISO, the term “trueness” is used in this document when referring to the closeness of the agreement between the average value from a large series of measurements to a true value of a measurand. The term “accuracy,” in its metrological sense, refers to the closeness of the agreement between the result of a (single) measurement and a true value of a measurand, thus comprising both random and systematic effects.

All terms and definitions will be reviewed again for consistency with international use, and revised appropriately during the next scheduled revision of this document.

The Subcommittee on Point-of-Care Coagulation Testing appreciates the opinions of manufacturers and users of POC-CT devices. We encourage all to participate in the consensus process by submitting written comments on content and format to the NCCLS Executive Offices. The subcommittee will consider all comments when it revises this guideline for the next edition.

Key Words

Calibration, point-of-care testing, quality assurance, quality control, safety

Point-of-Care Monitoring of Anticoagulation Therapy; Approved Guideline

1 Scope

This document deals only with the use of POC-CT in monitoring of anticoagulant therapy with unfractionated heparin (hereafter called “heparin”) and warfarin. It does not address issues related to the use of POC-CT in the evaluation of patients with suspected hemostatic disorders or use of other anticoagulants. There are many potential sites for POC-CT, such as hospitals, physicians’ offices, and patients’ homes. Those performing POC-CT may include healthcare professionals and patient caregivers, as well as patients.

2 Introduction

Advances in technology and the development of microtechniques and portable test instruments have made it possible to move medical testing closer to the patient. Point-of-care coagulation testing (POC-CT), is intended to provide test results more rapidly, efficiently, and conveniently than can be achieved in the clinical laboratory. This is particularly important in intensive care units, emergency rooms, operating rooms, and outpatient clinics where it may help expedite treatment decisions. POC-CT may also provide greater access to testing for the patient and/or caregiver, whether in the clinic or home setting. POC-CT may also reduce errors due to incorrect or delayed test result transmission to the patient/caregiver and thus improve overall quality of care. The guideline provides information and suggestions for good medical testing practice to produce accurate test results regardless of where, and by whom, testing is performed.

3 Standard Precautions

Because it is often impossible to know what might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all infectious agents and thus are more comprehensive than universal precautions which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the U.S. Centers for Disease Control and Prevention (*Guideline for Isolation Precautions in Hospitals*. Infection Control and Hospital Epidemiology. CDC. 1996;17(1):53-80 and *MMWR* 1988;37:377-388). For specific precautions for preventing the laboratory transmission of all infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all infectious disease, refer to the most current edition of NCCLS document M29—*Protection of Laboratory Workers from Occupationally Acquired Infections*.

4 Definitions

Accuracy (of measurement) – Closeness of the agreement between the result of a measurement and a true value of the measurand (VIM93)¹; **NOTE:** See **Measurand**.

Activated clotting time, ACT – A global coagulation test which is particularly sensitive to abnormalities in the intrinsic blood coagulation pathway and the anticoagulant activity of heparin; **NOTE:** The ACT is a measurement of the time in seconds required for a clot to form in a native (i.e., nonanticoagulated) blood specimen which has been exposed to a contact activator of the intrinsic phase blood coagulation pathway.